Uncomplicated falciparum malaria — DTM&H MCQ

Correct answer: C — Artemether-lumefantrine for 3 days

Artemether-lumefantrine for 3 days (option A) is correct because this is uncomplicated falciparum malaria (no severity features, low parasitaemia at 0.01%) acquired in a chloroquine-resistant area, and current UK guidance recommends an oral artemisinin-based combination therapy as first-line treatment in this setting. Adults with uncomplicated P. falciparum malaria should be treated with an ACT such as artemether-lumefantrine, which is highly effective, well tolerated and completes therapy quickly, reducing risk of progression to severe disease. The three-month delay to presentation is typical for falciparum, especially if chemoprophylaxis was used, and does not itself indicate severity or need for parenteral therapy. Because there are no severity criteria (no impaired consciousness, acidosis, renal impairment, hypoglycaemia, high parasitaemia, or shock), oral ACT rather than intravenous artesunate is appropriate. Why the other options are wrong: A. Intravenous artesunate for at least 24 hours: this is reserved for severe or complicated falciparum malaria (parasitaemia typically over 2%, organ dysfunction, or inability to tolerate oral therapy), none of which apply here. D. Atovaquone-proguanil for 3 days: an acceptable alternative ACT-equivalent oral option but not the first choice ahead of artemether-lumefantrine in UK guidance for uncomplicated falciparum malaria; it is usually reserved for patients unable to take artemether-lumefantrine or with contraindications. B. Oral quinine for 7 days plus doxycycline: effective but poorly tolerated (cinchonism, prolonged course, poor compliance) and superseded by ACTs as first line for uncomplicated disease. E. Chloroquine for 3 days: falciparum malaria from the Democratic Republic of Congo is chloroquine-resistant, so chloroquine has no role. Key point: uncomplicated P. falciparum malaria, regardless of low parasitaemia or delayed presentation, is treated with a first-line oral ACT (artemether-lumefantrine), reserving IV artesunate strictly for cases meeting severity criteria.

Reference: Public Health England Advisory Committee on Malaria Prevention (PHE ACMP), UK malaria treatment guidelines 2016, Journal of Infection (updated guidance summarised in PMC7132403): recommends artemisinin-based combination therapy (artemether-lumefantrine) as first-line treatment for uncomplicated P. falciparum malaria, with IV artesunate reserved for severe malaria. https://pmc.ncbi.nlm.nih.gov/articles/PMC7132403/